Shanghai Allist Pharmaceuticals (688578) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached RMB 1.58 billion, up 110.57% year-over-year, driven by strong sales of the core product after inclusion in the national medical insurance directory.

• Net profit attributable to shareholders was RMB 656 million, a 214.82% increase year-over-year, with effective cost control and improved operational efficiency.

• Cash flow from operating activities surged 293.73% year-over-year to RMB 730 million, reflecting robust sales growth.

• The company proposes a cash dividend of RMB 2.50 per 10 shares, totaling RMB 112.5 million.

Financial highlights

• Revenue: RMB 1,576,480,088.85 (+110.57% YoY).

• Net profit attributable to shareholders: RMB 656,136,849.43 (+214.82% YoY).

• Operating cash flow: RMB 730,267,159.10 (+293.73% YoY).

• Basic and diluted EPS: RMB 1.46 (+217.39% YoY).

• R&D investment: RMB 131 million, stable YoY, but as a percentage of revenue decreased to 8.33%.

Outlook and guidance

• Continued focus on innovative drug R&D, especially in targeted therapies for non-small cell lung cancer (NSCLC).

• Expansion of clinical indications for core products and ongoing development of new pipeline assets.

• Strengthening commercialization and sales network to further increase market share.